Develops fast-dissolving oral wafers carrying pharmaceutical agents, including cannabis extracts, for pharmaceutical companies.
10-K for FY2014, filed Apr 14, 2015
No revenue reported yet.
10-K for FY2014, filed Apr 14, 2015
Plans to seek pharmaceutical companies for joint ventures or licensing, and companies in multiple countries for exclusive rights to distribute its cannabis wafers.
10-K for FY2014, filed Apr 14, 2015
8-K, filed Aug 12, 2026
CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) received a continuation-in-part (CIP) approval from The United States Patent Office for the…View ↗
8-K, filed Feb 11, 2016
Effective February 8, 2015, Lucie Letellier tendered her resignation as the Company’s Chief Financial Officer. There was no disagreement…View ↗
8-K, filed Nov 3, 2015
The consulting agreements represent fully-vested, non-forfeitable equity interests in which case the liability of $906,250 to issue common…View ↗
From mineral exploration to drug delivery
The earlier report focuses on graphite exploration and mineral projects; the latest report makes oral drug delivery systems the business focus.
10-K for FY2011, filed Mar 20, 2012 10-K for FY2014, filed Apr 14, 2015Up until the Company’s distribution of most of the shares of Northern Graphite owned by the Company in January of 2012, the Bissett Creek…View ↗
Effective January 2nd, 2012, Mindesta entered into an option agreement with Nubian Gold Corporation (“Nubian”), a privately owned Ontario…View ↗
In 2012, Mindesta plans on focusing its efforts on mineral exploration in East Africa, and in particular the Republic of Somaliland and…View ↗
Loading...